HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belani, C. P. Search for Related Content PubMed PubMed Citation Articles by Belani, C. P.

Combined Modality Therapy for Unresectable Stage III Non-Small Cell Lung Cancer^*

New Chemotherapy Combinations

^* From the Division of Medical Oncology, Department of Medicine, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA.

Correspondence to: Chandra P. Belani, MD, University of Pittsburgh Cancer Institute, 200 Lothrop St, MUH N-725, Pittsburgh, PA 15213; e-mail: belanicp{at}msx.upmc.edu

Over the last decade, we have witnessed improved outcome among patients with non-small cell lung cancer (NSCLC), principally through the use of new and novel treatment programs. A meta-analysis of randomized clinical trials comparing combined chemotherapy and radiation to radiation therapy alone clearly has shown a survival benefit with platinum-based combination chemotherapy administered sequentially or concurrently with thoracic radiation therapy over radiation therapy alone. In addition, combining thoracic radiation therapy with novel drugs or new drug combinations has yielded improvements in median survival duration and long-term survival rates in locally advanced unresectable NSCLC. Paclitaxel and carboplatin are two novel agents that have undergone extensive clinical evaluation at various doses and schedules in combination with thoracic radiation therapy in patients with locally advanced disease. There remains a need, however, for further improvement in metastatic control and prevention of locoregional recurrences. This will likely be achieved through the optimization of chemotherapy regimens to be used in combined modality therapy with thoracic radiation therapy.

Key Words: combined modality • esophagitis • non-small cell lung cancer • radiosensitization • survival • therapy • thoracic radiation

This article has been cited by other articles:

				H. J. M. Groen, A. H. W. van der Leest, E. Fokkema, P. R. Timmer, G. D. Nossent, W. J. G. M. Smit, J. Nabers, H. J. Hoekstra, J. Hermans, R. Otter, et al. Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study Ann. Onc., March 1, 2004; 15(3): 427 - 432. [Abstract] [Full Text] [PDF]

				K. S. Albain, J. J. Crowley, A. T. Turrisi III, D. R. Gandara, W. B. Farrar, J. I. Clark, K. R. Beasley, and R. B. Livingston Concurrent Cisplatin, Etoposide, and Chest Radiotherapy in Pathologic Stage IIIB Non-Small-Cell Lung Cancer: A Southwest Oncology Group Phase II Study, SWOG 9019 J. Clin. Oncol., August 15, 2002; 20(16): 3454 - 3460. [Abstract] [Full Text] [PDF]